Your browser doesn't support javascript.
loading
Deep Brain Stimulation of the Medial Forebrain Bundle for Treatment-Resistant Depression: A Systematic Review Focused on the Long-Term Antidepressive Effect.
Remore, Luigi Gianmaria; Tolossa, Meskerem; Wei, Wexin; Karnib, Mohammad; Tsolaki, Evangelia; Rifi, Ziad; Bari, Ausaf Ahmad.
Affiliation
  • Remore LG; Department of Neurosurgery, University of California Los Angeles, Los Angeles, CA, USA; University of Milan "La Statale," Milan, Italy. Electronic address: luigigianmaria.remore@gmail.com.
  • Tolossa M; Department of Neurosurgery, University of California Los Angeles, Los Angeles, CA, USA.
  • Wei W; Department of Neurosurgery, University of California Los Angeles, Los Angeles, CA, USA.
  • Karnib M; University of California Los Angeles, Los Angeles, CA, USA.
  • Tsolaki E; Department of Neurosurgery, University of California Los Angeles, Los Angeles, CA, USA.
  • Rifi Z; University of California Los Angeles, Los Angeles, CA, USA.
  • Bari AA; Department of Neurosurgery, University of California Los Angeles, Los Angeles, CA, USA; David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Neuromodulation ; 2023 Apr 26.
Article in En | MEDLINE | ID: mdl-37115122
ABSTRACT

OBJECTIVE:

Major depression affects millions of people worldwide and has important social and economic consequences. Since up to 30% of patients do not respond to several lines of antidepressive drugs, deep brain stimulation (DBS) has been evaluated for the management of treatment-resistant depression (TRD). The superolateral branch of the medial forebrain bundle (slMFB) appears as a "hypothesis-driven target" because of its role in the reward-seeking system, which is dysfunctional in depression. Although initial results of slMFB-DBS from open-label studies were promising and characterized by a rapid clinical response, long-term outcomes of neurostimulation for TRD deserve particular attention. Therefore, we performed a systematic review focused on the long-term outcome of slMFB-DBS. MATERIALS AND

METHODS:

A literature search using Preferred Reporting Items for Systematic Reviews and Meta-Analyses criteria was conducted to identify all studies reporting changes in depression scores after one-year follow-up and beyond. Patient, disease, surgical, and outcome data were extracted for statistical analysis. The Montgomery-Åsberg Depression Rating Scale (ΔMADRS) was used as the clinical outcome, defined as percentage reduction from baseline to follow-up evaluation. Responders' and remitters' rates were also calculated.

RESULTS:

From 56 studies screened for review, six studies comprising 34 patients met the inclusion criteria and were analyzed. After one year of active stimulation, ΔMADRS was 60.7% ± 4%; responders' and remitters' rates were 83.8% and 61.5%, respectively. At the last follow-up, four to five years after the implantation, ΔMADRS reached 74.7% ± 4.6%. The most common side effects were stimulation related and reversible with parameter adjustments.

CONCLUSIONS:

slMFB-DBS appears to have a strong antidepressive effect that increases over the years. Nevertheless, to date, the overall number of patients receiving implantations is limited, and the slMFB-DBS surgical technique seems to have an important impact on the clinical outcome. Further multicentric studies in a larger population are needed to confirm slMFB-DBS clinical outcomes.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Prognostic_studies / Systematic_reviews Language: En Journal: Neuromodulation Year: 2023 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Prognostic_studies / Systematic_reviews Language: En Journal: Neuromodulation Year: 2023 Type: Article